Erdanat 3mg Tablet is an anticancer medication containing the active constituent erdafitinib. It is used to treat a type of cancer known as locally advanced or metastatic urothelial carcinoma, which mainly affects the bladder and urinary tract. This medicine is generally prescribed for patients whose cancer has specific genetic changes in fibroblast growth factor receptor (FGFR) genes and who have already received prior chemotherapy.

Erdanat 3mg Tablet is a targeted therapy that helps slow down or stop the growth of cancer cells by blocking certain proteins involved in tumor development. It is taken orally and requires close monitoring, especially for eye-related side effects and changes in blood phosphate levels. Erdanat Tablet substitutes include one that contains erdafitinib.

Patients should inform their doctor if they experience vision changes, eye pain, or dry eyes. Regular eye examinations and blood tests are important during treatment. Individuals with a history of eye disorders or kidney problems should consult their healthcare provider before starting this medicine.

• Locally advanced urothelial carcinoma.
• Metastatic urothelial carcinoma with FGFR genetic alterations.

Erdanat 3mg Tablet works by inhibiting fibroblast growth factor receptor (FGFR) 1–4, which are proteins involved in cell growth and survival. In some cancers, these receptors are overactive due to genetic mutations, leading to uncontrolled tumor growth. By blocking these receptors, this medicine slows down the growth of cancer cells and may help shrink tumors.

Erdanat 3mg Tablet is taken orally as a tablet, usually once daily or as prescribed by the doctor. It should be swallowed whole with or without food. The dosage may be adjusted based on blood phosphate levels and treatment response. Do not crush or chew the tablet. Do not take a double Erdanat 3mg Tablet dosage to make up for a missed one.

Serious:

Eye disorders such as central serous retinopathy

Severe hyperphosphatemia (high phosphate levels)

Hand-foot syndrome

Severe skin reactions

Nail disorders

Stomatitis (inflammation of the mouth)

Common:

Dry mouth

Fatigue

Diarrhoea

Decreased appetite

Tastes change

Dry skin

Hair thinning

Constipation

Taking Erdanat 3mg Tablet with any of the following medicines can alter the effects of either and may increase the risk of serious side effects.

Strong CYP3A4 inhibitors such as Ketoconazole or Clarithromycin (Oral Route) Moderate

Use with caution.

These medicines may increase erdafitinib levels, leading to increased side effects.

Strong CYP3A4 inducers such as Rifampicin or Phenytoin (Oral Route) Moderate

Avoid concomitant use.

These medicines may reduce the effectiveness of erdafitinib.

Phosphate-lowering agents (Oral Route) Moderate

Use with caution.

They may interfere with monitoring phosphate levels, which is important during treatment.

Other anticancer medicines (Oral/Injection Route) Moderate

Use carefully.

May increase the risk of combined toxicity.

• Store Erdanat 3mg Tablet at room temperature (20°C to 25°C).
• Keep it in a dry place away from moisture and heat.
• Protect from light.
• Keep it in its original packaging until use.
• Keep out of the reach of children and pets.
• Dispose of properly as per medical guidelines.

• Attend regular eye check-ups during treatment.
• Drink adequate fluids and maintain good oral hygiene.
• Report any vision changes or eye discomfort immediately.
• Follow dietary advice to manage phosphate levels.
• Avoid self-medication and inform your doctor about all medicines you are taking.
• Use effective contraception during and after treatment as advised.